Oxford BioTherapeutics

Oxford BioTherapeutics is an Oxford-based clinical-stage oncology company discovering and developing first-in-class antibody-based cancer therapies.

Its proprietary platform identifies novel membrane protein targets directly from patient tumour samples, enabling the development of ADCs, immuno-oncology antibodies, T-cell engagers, and CAR-T targets.

The company licenses discovered targets and development candidates to major pharmaceutical partners including Bristol Myers Squibb, Roche, GSK, and Boehringer Ingelheim.